1. Scrip

Sanofi Chief Issues Warning To Innovation-Unfriendly EU

 
• By Kevin Grogan

Paul Hudson told Scrip that while the EU's prioritization on matters such as boosting hydrogen use and electric car batteries was laudable, delivery of healthcare and the innovation associated with it should be "a strategic imperative."

Paul Hudson
Paul Hudson • Source: Sanofi

Sanofi CEO Paul Hudson has again spoken out about plans to overhaul EU pharmaceutical legislation and its negative impact on innovative R&D firms, saying further obstacles to market access will hamper the continent's efforts to compete with the US and China.

In response to questions from Scrip at the French giant's annual press conference in Paris this week (1 February), Hudson...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Executives On The Move: Fable Therapeutics Gains CMO From AstraZeneca

Recent moves in the industry include changes at the top at 32 Biosciences, plus new CEOs at Idorsia, Courage Therapeutics and Oncolytics Biotech.

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.